Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.

The oncologist - 1 Jul 2015

Latimer Nicholas R, Abrams Keith R, Amonkar Mayur M, Stapelkamp Ceilidh, Swann R Suzanne

Abstract excerpt

BACKGROUND: Patients with previously untreated BRAF V600E mutation-positive melanoma in BREAK-3 showed a median overall survival (OS) of 18.2 months for dabrafenib versus 15.6 months for dacarbazine (hazard ratio [HR], 0.76; 95% confidence interval, 0.48-1.21). Because patients receiving dacarbazine were allowed to switch to dabrafenib at disease progression, we attempted to adjust for the confounding effects on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Imidazoles

Share to Kaplan-Meier Estimate

Share to Melanoma

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 26040620
DOI: 10.1634/theoncologist.2014-0429
PMCID: PMC4492231

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.PMID 26040620Read ↗

Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.Semantic proximity Read ↗

An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib.Semantic proximity Read ↗

Clinical significance on Switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancerSemantic proximity Read ↗

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction.Semantic proximity Read ↗

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.Semantic proximity Read ↗

INCIDENCE AND ASSOCIATED FACTORS WITH THE CHANGE FREE TIME BETWEEN THE BRANDED OR GENERIC IMATINIB IN NAIVE PATIENTS WITH CHRONIC MYELOID LEUKEMIASemantic proximity Read ↗

Efficacy and Tolerability of Generic Pirfenidone After Switch from Esbriet® in Idiopathic Pulmonary Fibrosis: A Real-World Observational StudySemantic proximity Read ↗

Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.Semantic proximity Read ↗

Challenges of guarantee-time bias.Semantic proximity Read ↗

Safety of rituximab biosimilar (Riximyo®) following a single switch from the reference product in patients with Non-Hodgkin’s Lymphoma: A Retrospective StudySemantic proximity Read ↗

The Case Against Censoring of Progression-Free Survival in Cancer Clinical Trials – A Pandemic Shutdown as an IllustrationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.